Eupraxia Pharmaceuticals (EPRX) Minority Interest (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Minority Interest for 5 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Minority Interest fell 1.67% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$1.6 million (down 1.67% YoY), while the FY2025 annual figure was -$1.6 million, down 1.88% from the prior year.
• Minority Interest steadied at -$1.6 million in Q1 2026 per EPRX's latest filing, from -$1.6 million in the prior quarter.
• Across five years, Minority Interest topped out at -$578671.0 in Q4 2022 and bottomed at -$1.6 million in Q1 2026.
• Historically, Minority Interest has averaged -$1.4 million across 5 years, with a median of -$1.6 million in 2024.
• Annual changes were most pronounced in 2023 — Minority Interest tumbled 128.78% — and 2026, when it declined 1.67%.
• Eupraxia Pharmaceuticals' Minority Interest stood at -$578671.0 in 2022, then tumbled by 128.78% to -$1.3 million in 2023, then retreated by 18.28% to -$1.6 million in 2024, then dropped by 1.88% to -$1.6 million in 2025, then decreased by 0.09% to -$1.6 million in 2026.
• Business Quant data shows EPRX's Minority Interest at -$1.6 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.6 million in Q3 2025.